[go: up one dir, main page]

EA201800499A1 - Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор - Google Patents

Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор

Info

Publication number
EA201800499A1
EA201800499A1 EA201800499A EA201800499A EA201800499A1 EA 201800499 A1 EA201800499 A1 EA 201800499A1 EA 201800499 A EA201800499 A EA 201800499A EA 201800499 A EA201800499 A EA 201800499A EA 201800499 A1 EA201800499 A1 EA 201800499A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lateral sclerosis
inhibitor
treatment
thyrozinkinase
medicine
Prior art date
Application number
EA201800499A
Other languages
English (en)
Other versions
EA038531B1 (ru
Inventor
Алан Мюсси
Жан-Пьер Кине
Колин Менсфилд
Original Assignee
Аб Сьянс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аб Сьянс filed Critical Аб Сьянс
Publication of EA201800499A1 publication Critical patent/EA201800499A1/ru
Publication of EA038531B1 publication Critical patent/EA038531B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к способу лечения пациентов, страдающих неагрессивным или умеренно агрессивным боковым амиотрофическим склерозом (БАС) со скоростью роста показателя согласно переработанной Шкале нарушений функций при боковом амиотрофическом склерозе (ALSFRS-R) <1,1 балла в месяц до начала лечения, включающему введение ингибитора тирозинкиназ или ингибитора мастоцитов, в частности мазитиниба или его фармацевтически приемлемой соли или сольвата необязательно в сочетании по меньшей мере с одним действующим фармацевтическим ингредиентом.
EA201800499A 2016-03-25 2017-03-24 Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб EA038531B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16162490 2016-03-25
PCT/EP2017/057134 WO2017162884A1 (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Publications (2)

Publication Number Publication Date
EA201800499A1 true EA201800499A1 (ru) 2019-03-29
EA038531B1 EA038531B1 (ru) 2021-09-10

Family

ID=55637258

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201800499A EA038531B1 (ru) 2016-03-25 2017-03-24 Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб

Country Status (20)

Country Link
US (1) US10092564B2 (ru)
EP (1) EP3240538B1 (ru)
JP (2) JP7250312B2 (ru)
KR (1) KR102293847B1 (ru)
CN (1) CN108883108B (ru)
AU (1) AU2017236177B2 (ru)
BR (1) BR112018069515A2 (ru)
CA (1) CA3018635C (ru)
DK (1) DK3240538T3 (ru)
EA (1) EA038531B1 (ru)
ES (1) ES2899929T3 (ru)
HU (1) HUE057398T2 (ru)
IL (1) IL261856B (ru)
MX (1) MX390495B (ru)
NZ (1) NZ745778A (ru)
PL (1) PL3240538T3 (ru)
PT (1) PT3240538T (ru)
SG (1) SG11201808106YA (ru)
SI (1) SI3240538T1 (ru)
WO (1) WO2017162884A1 (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
AU2013334874B2 (en) 2012-10-25 2018-04-05 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20190240194A1 (en) * 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
CN115025225A (zh) 2016-11-25 2022-09-09 基诺富公司 用于诱导神经干细胞的分化和保护的组合物及使用该组合物诱导神经再生的方法
CN110475555A (zh) * 2017-03-28 2019-11-19 诺华股份有限公司 治疗多发性硬化的新方法
CA3065365C (en) * 2017-05-30 2025-09-16 Deciphera Pharmaceuticals, Llc USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDINE-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ITS ANALOGUES FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN THE PLATELET-DERIVED GROWTH FACTOR ALPHA RECEPTOR
JP7463281B2 (ja) * 2018-03-05 2024-04-08 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド コロニー刺激因子を標的とすることによる、緑内障および視神経症のための療法
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
SG11202106117SA (en) 2018-12-10 2021-07-29 Massachusetts Gen Hospital Cromolyn esters and uses thereof
CN112618717A (zh) * 2019-09-24 2021-04-09 北京大学深圳研究生院 Btk抑制剂用于治疗肌萎缩侧索硬化症的用途
MX2022008097A (es) * 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Composiciones de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-dih idro-1,6-naftiridin-3-yl)-2-fluorofeil)-3-fenilurea.
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
WO2025113494A1 (zh) * 2023-11-27 2025-06-05 浙江径科医药有限公司 多环类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (ru) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US20050239852A1 (en) 2002-08-02 2005-10-27 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
AR065337A1 (es) 2007-02-13 2009-06-03 Ab Science Proceso para la sintesis de compuestos de 2- aminotiazol como inhibidores de quinasa, forma polimorfica
TW201204360A (en) 2010-04-20 2012-02-01 Ab Science Treatment of multiple sclerosis with MASITINIB
CN109316480A (zh) 2011-07-13 2019-02-12 赛特凯恩蒂克公司 组合als疗法
EP2903616B8 (en) * 2012-10-04 2018-02-07 AB Science Use of masitinib in combination with gemcitabine for treating a subgroup of patients suffering from pancreatic cancer
JP6553589B2 (ja) * 2013-03-15 2019-07-31 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド ピリミド−ジアゼピノン化合物および障害の治療方法
US20160263110A1 (en) * 2013-11-04 2016-09-15 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
IL261856A (en) 2018-10-31
PL3240538T3 (pl) 2022-01-31
SG11201808106YA (en) 2018-10-30
US10092564B2 (en) 2018-10-09
SI3240538T1 (sl) 2022-02-28
DK3240538T3 (da) 2021-12-06
MX2018011349A (es) 2019-02-07
JP2022037132A (ja) 2022-03-08
KR20180125966A (ko) 2018-11-26
EP3240538B1 (en) 2021-09-29
EP3240538A1 (en) 2017-11-08
US20180117037A1 (en) 2018-05-03
CN108883108A (zh) 2018-11-23
KR102293847B1 (ko) 2021-08-26
NZ745778A (en) 2022-07-01
BR112018069515A2 (pt) 2019-04-16
WO2017162884A1 (en) 2017-09-28
HUE057398T2 (hu) 2022-05-28
JP2019515884A (ja) 2019-06-13
EA038531B1 (ru) 2021-09-10
PT3240538T (pt) 2021-12-07
IL261856B (en) 2022-04-01
AU2017236177A1 (en) 2018-09-20
CA3018635C (en) 2023-09-26
ES2899929T3 (es) 2022-03-15
JP7250312B2 (ja) 2023-04-03
CN108883108B (zh) 2021-08-06
CA3018635A1 (en) 2017-09-28
AU2017236177B2 (en) 2022-03-31
MX390495B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
EA201800499A1 (ru) Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2021004431A (es) Procesos novedosos.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
SA518391624B1 (ar) Ror- منظمات جاما
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton&#39;s tyrosine kinase
WO2016109217A3 (en) Btk inhibitors
MX2023002321A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MA39765A (fr) Formulation pharmaceutique d&#39;un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d&#39;utilisation
NZ752587A (en) Lsd1 inhibitors and medical uses thereof
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
EP4285993A3 (en) Growth differentiation factor 15 as biomarker for metformin
MX2021013602A (es) Inhibidores de jak.
MA42301B1 (fr) Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone
PH12021550671A1 (en) Prodrugs of cgrp antagonists
MX377032B (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2016008968A (es) Compuestos organicos.
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors